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The HIV-1 viral accessory protein Vif prevents the encapsidation of the antiviral cellular cytidine deaminases APOBEC3F and
APOBEC3G by inducing their proteasomal degradation. In the absence of Vif, APOBEC3G is encapsidated and blocks virus replication by
deaminating cytosines of the viral cDNA. APOBEC3G encapsidation has been recently shown to depend on the viral nucleocapsid protein;
however, the role of RNA remains unclear. Using APOBEC3G deletion and point mutants, we mapped the encapsidation determinant to the
Zn2+ coordination residues of the N-terminal catalytic domain (CD1). Notably, these residues were also required for RNA binding. Mutations
in the two aromatic residues of CD1 but not CD2, which are conserved in cytidine deaminase core domains and are required for RNA
binding, prevented encapsidation into HIV-1, HTLV-I and MLV. The Zn2+ coordination residues of the C-terminal catalytic domain (CD2)
were not required for encapsidation but were essential for cytidine deaminase activity and the antiviral effect. These findings suggest a model
in which CD1 mediates encapsidation and RNA binding while CD2 mediates cytidine deaminase activity. Interestingly, HTLV-I was
relatively resistant to the antiviral effects of encapsidated APOBEC3G.
D 2005 Elsevier Inc. All rights reserved.
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Lentiviruses, with the exception of equine infectious
anemia virus, require the accessory protein Vif to replicate
in primary CD4+ T cells and monocytes. Vif has been shown
to relieve the inhibitory activity of cellular cytidine
deaminases of the APOBEC3 family (Sheehy et al.,
2002). APOBEC3F and APOBEC3G become encapsidated
in Dvif HIV-1 virions, causing CYU deamination of the
viral DNA that is synthesized in the subsequent round of
replication (Bishop et al., 2004; Harris et al., 2003;
Lecossier et al., 2003; Liddament et al., 2004; Mangeat et
al., 2003; Mariani et al., 2003; Wiegand et al., 2004; Zhang
et al., 2003; Zheng et al., 2004). The uracil-containing viral
cDNA molecules are degraded by cellular DNA repair0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: Landau@salk.edu (N.R. Landau).enzymes prior to integration. In cells infected with wild-type
HIV-1, Vif binds to APOBEC3G, inducing its rapid
ubiquitination and degradation before it can become
encapsidated (Mehle et al., 2004; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003). Vif-induced degrada-
tion of APOBEC3G is mediated by an E3 ubiquitin ligase of
the ECS type that is composed of elongins B and C, Cul5
and Rbx1 to which Vif binds (Yu et al., 2003).
APOBEC3 molecules are conserved in primate and
rodent genomes and are active against HIV-1 when
expressed in human cells (Mariani et al., 2003). However,
the interaction of Vif with APOBEC3G is species-specific
(Mariani et al., 2003). The mouse genome contains a single
APOBEC3 gene that is about ~30% identical to the human
orthologue. Mouse APOBEC3 blocked HIV-1 regardless of
the presence of Vif. Similarly, African green monkey
(AGM) and rhesus macaque APOBEC3Gs were active
against Dvif and wild-type HIV-1 (Mariani et al., 2003). The
species-specificity resulted from the inability of Vif to bind05) 374–386
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amino acid of APOBEC3G at position 128 (Bogerd et al.,
2004; Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et
al., 2004).
In humans, the APOBEC family of cytidine deaminases
includes APOBEC1, APOBEC2, APOBEC3A-G and the
activation induced deaminase (AID) (Harris et al., 2002;
Jarmuz et al., 2002). APOBEC1 is an RNA editing enzyme
which in a complex with APOBEC complementing factor
deaminates a single cytosine of apolipoprotein B mRNA to
introduce a termination codon. APOBEC1 also has non-
specific cytosine deaminase activity on DNA (Harris et al.,
2002). AID is required for somatic hypermutation and class
switch recombination (Muramatsu et al., 2000; Muto et al.,
2000; Revy et al., 2000) in B lymphocytes (Jarmuz et al.,
2002).
APOBEC family members contain a domain structure
characteristic of cytidine deaminases (Jarmuz et al., 2002).
A short a-helical domain is followed by a catalytic domain
(CD), a short linker peptide and a pseudocatalytic domain
(PCD). In APOBEC3B, APOBEC3F and APOBEC3G, the
entire unit is duplicated to form the domain structure helix1-
CD1-linker1-PCD1-helix2-CD2-linker2-PCD2. Each cata-
lytic domain contains the conserved motif H-X-E-(X)27–28-
P-C-X-X-C in which the His and Cys residues coordinate
Zn2+ and the Glu serves as a proton shuttle in the
deamination reaction (Betts et al., 1994; Wedekind et al.,
2003). CD1 and CD2 contain conserved aromatic residues
located between the H-X-E and P-C-X-X-C residues (Phe70
and Tyr91 in CD1 and Phe262 and Phe282 in CD2) that in
APOBEC1 are required for RNA binding (Navaratnam et
al., 1995).
The mechanism by which APOBEC3G is encapsidated
in HIV-1 virions has been the subject of several recent
reports. There is general agreement that encapsidation is
dependent upon the nucleocapsid (NC) domain of Gag
(Alce and Popik, 2004; Cen et al., 2004; Douaisi et al.,
2004; Luo et al., 2004; Schafer et al., 2004; Zennou et al.,
2004). Interaction between APOBEC3G and NC has been
shown by GST-pull down assays (Alce and Popik, 2004;
Douaisi et al., 2004), coimmunoprecipitation experiments
(Cen et al., 2004; Luo et al., 2004; Zennou et al., 2004) and
also in a binding assay using in vitro translated proteins
(Schafer et al., 2004). NC also serves to capture the viral
genomic RNA and thus it is possible that the RNA can
contribute to APOBEC3G encapsidation. Evidence showing
that purified recombinant APOBEC3G and NC directly
interact (Alce and Popik, 2004) and that RNase A treatment
does not alter the ability to coimmunoprecipitate Gag and
APOBEC3G (Cen et al., 2004; Douaisi et al., 2004) would
suggest no requirement for RNA. However, others have
found that the interaction was sensitive to ribonucleases
(Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al.,
2004).
Here, we further defined the determinants of APO-
BEC3G that are required for encapsidation. Our resultsshow that the critical domain of APOBEC3G required for
encapsidation mapped to the conserved Zn2+ coordinating
residues of the N-terminal catalytic domain (CD1) and that
these residues are required for RNA binding. Mutational
analyses showed that CD1 was important for RNA binding,
homodimerization and encapsidation, while CD2 was the
catalytically active site. The findings suggest that APO-
BEC3G CD1 serves as the encapsidation and dimerization
domain and CD2 catalyzes deamination of the reverse
transcripts.Results
Virions deleted for NC encapsidate a significant amount of
APOBEC3G
Several reports have demonstrated the dependence of
APOBEC3G encapsidation on the Gag nucleocapsid (NC)
(Alce and Popik, 2004; Cen et al., 2004; Douaisi et al.,
2004; Luo et al., 2004; Schafer et al., 2004; Svarovskaia
et al., 2004; Zennou et al., 2004). However, in our
analysis of a minimal Gag that was deleted for NC,
called Zwt, we found a small but consistent amount of
APOBEC3G (Fig. 1A). In this construct, NC is replaced
by the leucine zipper domain of the yeast transcription
factor GCN4 and lacks p1 and p6 (Accola et al., 2000).
To determine whether this might have been due to over-
expression of APOBEC3G, we tested its encapsidation
over a wide range of expression levels, comparing to
full-length construct, Pr55 (Fig. 1A). Because Zwt
expressed Vif, the APOBEC3G with a D128K mutation
which prevents the interaction with HIV-1 Vif was used
(Schrofelbauer et al., 2004). Zwt particles consistently
encapsidated about 10-fold less APOBEC3G than Pr55
over the range of concentrations. The amount of
APOBEC3G synthesized in the cells was proportional
to the amount of plasmid in the transfection. Thus, in
agreement with the findings of others (Alce and Popik,
2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al.,
2004; Schafer et al., 2004; Zennou et al., 2004), NC was
an important determinant of APOBEC3G encapsidation,
but a significant amount of APOBEC3G encapsidation
occurred even in the absence of NC. Quantitation of the
viral RNA content of the Zwt virions by dot blot,
showed that even without NC a small amount of viral
RNA had been packaged (Fig. 1A, bottom). These results
suggested that APOBEC3G could be encapsidated inde-
pendent of NC, perhaps as a result of binding to RNA.
The viral RNA is not required
To determine whether this could have been due to an
association with the viral RNA, we analyzed APO-
BEC3G incorporation into virus particles that lacked
viral genomic RNA. We generated VLPs using a CMV-
Fig. 1. Encapsidation of significant amounts of APOBEC3G into NC-deleted virions and lack of requirement for viral RNA. (A) Virions composed of full-
length Gag Pr55 or deleted Gag lacking NC, p1 and p6 (diagrammed above) were generated in the presence of decreasing amounts of HA tagged APOBEC3G
expression vector. The amount of pcAPOBEC3G-HA transfected is indicated above in Ag. APOBEC3G content of the virions and transfected cells was
analyzed on immunoblots probed with anti-HA Mab. The blots were reprobed with anti-p24 MAb to determine the amount of virions. (B) Virions lacking viral
genomic RNA were tested for APOBEC3G encapsidation using the gag-pol expression vector pMDL-RRE (diagrammed above). For this experiment, the
amount of particles was normalized by p24. Arrows on the left indicate the position of APOBEC3G, CA, Pr55 and Zwt. Dot blot measurement of the viral
RNA content of the virions is shown at the bottom. Controls are included for transfection of a NL4-3 with a stop codon in Gag (Gag) and lacking viral DNA
(empty). PhosphoImager quantitation of the band intensities is shown below.
F. Navarro et al. / Virology 333 (2005) 374–386376driven Gag-Pol expression vector pMDL-RRE that
lacked the packaging sequences upstream the gag.
These VLPs contained wild-type amounts of APO-
BEC3G (Fig. 1B, middle) but contained no detectable
viral RNA (Fig. 1B, bottom). The strength of the signal
in the DVif particles as compared to the Gag-Pol
particles (Fig. 1B, bottom) clearly showed that APO-
BEC3G encapsidation is not dependent on the viral
genomic RNA, which is consistent with previous
findings (Cen et al., 2004; Svarovskaia et al., 2004;
Zennou et al., 2004).
APOBEC3G encapsidation requires the Zn2+ coordination
residues of CD1
The feature of APOBEC family proteins that allows
their encapsidation into retroviral virions is not known. Tomap the domains of APOBEC3G required for encapsida-
tion, we generated a panel of APOBEC3G deletion mutants
(Fig. 2A) and tested their encapsidation into DVif HIV-1
particles. With the exception of the N-terminal fragment,
the deleted proteins were stably expressed in transfected
cells. For several of the deletion mutants additional bands
were seen on the blots which might correspond to products
of degradation or post-translational modifications (Fig. 2B;
the bands corresponding to the expected sizes are indicated
with an asterisk). It is of note that several species of
different mobility were detected as well for APOBEC3G
wild type. Importantly, none of the deletion mutants was
efficiently encapsidated (Fig. 2B). Deletion of as little as
the first 54 amino acids prevented encapsidation.
To further define critical amino acid residues for
encapsidation, point mutants of the conserved residues of
the zinc finger motifs in CD1 and CD2 were tested (Fig. 3A).
Fig. 2. Encapsidation of APOBEC3G deletion mutants into DVif NL4-3 virus particles. (A) Diagrams of APOBEC3G deletion mutants. The numbers indicate
amino acid positions in human APOBEC3G. All deletion constructs contain a HA-tag at the carboxy terminus of the protein. (B) APOBEC3G deletion
constructs were cotransfected with the proviral DNA into 293T cells. Cell lysates and viruses were prepared 48 h after transfection and proteins were analyzed
by immunoblotting. Full-length and mutant APOBEC3Gs were detected using an anti-HA antibody. Viral Gag proteins were detected by an anti-p24 antibody.
Comparable amounts of virus particles were used, as indicated by immunoblotting with the anti-p24 MAb. Quantitative analysis, calculated as the relative ratio
of APOBEC3G in virions as compared to cell lysates and normalized for the ratio obtained with APOBEC3G wild-type, is shown below.
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catalytic Glu67 in CD1 (Zn1) to Ala prevented encap-
sidation (Fig. 3B). Mutation of the analogous amino
acids in CD2 (Zn2), in contrast, had no significant effect.
The double mutant (Zn1/2) was also not encapsidated
(Fig. 3B). Thus, the conserved residues of CD1 but not
CD2 were critical for encapsidation. The mutated proteins
were stably expressed although those with mutations in
CD1 were expressed with a modest decrease in steady-
state level.
Mutation of the Zn2+ coordinating Cys residues, Cys97
and Cys100, of CD1 to Ala (1CCAA) was sufficient to
substantially reduce encapsidation (Fig. 3C). The analogous
mutations in CD2 of Cys288 and Cys291 to Ala (2CCAA)
had no significant effect. Mutation of the Zn2+ coordination
Cys residues in CD1 to Ser, a more conservative change,
also substantially reduced encapsidation (Fig. 3C).
Additional mutants were tested in which two conserved
aromatic residues within the core motif that have been
shown to mediate RNA binding (Navaratnam et al., 1995)
were changed to Ala. Mutations F70A/Y91A in CD1
(1FYAA) prevented encapsidation (Fig. 3C). The analogous
change in CD2 of F262A/F282A (2FFAA) also decreased
encapsidation, although its effect was not as pronounced as
in the 1FYAA mutant (Fig. 3C). These findings suggested
that the Zn2+ coordinating residues and the conserved
residues involved in RNA binding in CD1 were critical
for APOBEC3G encapsidation.To further test the role of the conserved residues, single
point mutants were analyzed. Single mutations in the CD1
Zn2+ coordination residues H65A, C97A and C100A all
prevented or reduced encapsidation, while mutation of the
catalytic Glu67 had no significant effect (Fig. 4A).
Similarly, mutation of the catalytic residue Glu259 had no
major effect on encapsidation (Fig. 4A). All of the proteins
were stably expressed although, changes in the Zn2+
coordination residues caused a 2- to 4-fold decrease in
steady-state level suggesting that these residues also play a
structural role in the enzyme. Taken together, these findings
suggested the Zn2+ coordination residues of CD1 are critical
for encapsidation.
The catalytic residue Glu259 in CD2 is required for
antiviral activity
The contribution of the conserved amino acids of the
zinc finger motifs in CD1 and CD2 to the antiviral activity
of APOBEC3G was determined by single-cycle luciferase
reporter virus assay. The CD1 mutants Zn1, Zn1/2,
1CCAA, 1FYAA and the CD2 mutant 2FFAA which were
poorly encapsidated had no effect on infectivity (Fig. 4B,
top). The CD2 mutants Zn2 and 2CCAA also had no
effect on infectivity, despite of being efficiently encapsi-
dated (Fig. 4B, top). Single amino acid mutations of the
Zn2+ coordination residues His65, Cys97 and Cys100 of
CD1 had no major effect on infectivity (Fig. 4B, bottom).
Fig. 3. The Zn2+ coordination residues of CD1 are required for efficient encapsidation. Virions were generated with Dvif NL4-3 (Dvif) and the mutated
APOBEC3G-HA expression vector indicated above each lane. (A) Diagram showing the altered conserved residues on each mutant. (B) APOBEC3G mutated
in the active site motif of CD1 (Zn1), CD2 (Zn2) or CD1 and CD2 (Zn1/2). APOBEC3G content was analyzed on immunoblots probed with anti-HA MAb.
The position of APOBEC3G and CA is indicated by arrows on the left. (C) APOBEC3G mutated in the Zn2+ coordination residues and aromatic conserved
RNA binding residues of CD1 and CD2. Quantitative analysis, as performed in Fig. 1, is shown for panels B and C.
F. Navarro et al. / Virology 333 (2005) 374–386378Importantly, mutation of the CD1 catalytic residue Glu67
did not reduce antiviral activity. In contrast, mutation of
the analogous CD2 amino acid, Glu259, largely dimin-
ished the antiviral effect (Fig. 4B, bottom). These findings
suggested that the catalytic activity that deaminates the
viral genome is primarily mediated by CD2.
Cytidine deaminase activity resides in CD2
To directly test the relative contributions of the active
sites, we measured cytidine deaminase activity of the
mutant proteins. The mutant proteins were encapsidated
in virions and then released by detergent solubilization.
Cytidine deaminase activity was tested using a 5V-end
labeled oligonucleotide substrate that contained a consensus
CCCA target site (Yu et al., 2004b). The molecules were
cleaved at the deaminated dU by treatment with uracil DNA
glycosylase and NaOH and detected by autoradiography.
The 1CCAA mutant was partially active while the 2CCAA
was inactive (Fig. 5). The partial activity of 1CCAA shouldbe considered in light of its inefficient encapsidation. This
mutant may be almost fully active on a molar basis.
Importantly, mutation of the CD1 catalytic amino acid
Glu67 resulted in a fully active enzyme, while mutation of
the analogous CD2 amino acid in Glu259 inactivated the
enzyme. Thus, CD2 appeared to mediate deamination of
DNA.
RNA binding requires the Zn2+ coordination residues of
CD1
It has been described that APOBEC3G is able to bind
RNA in vitro (Jarmuz et al., 2002; Yu et al., 2004b). To
determine the relative contribution of the Zn2+ coordina-
tion residues of CD1 and CD2 to the ability of
APOBEC3G to bind RNA, recombinant proteins with
mutations in these residues were tested for RNA binding
by EMSA (Yu et al., 2004b). Wild-type, 1CCAA and
2CCAA mutant APOBEC3Gs were purified from E. coli
as glutathione S-transferase (GST) fusion proteins. In
Fig. 4. Mutations in the conserved Zn2+ coordinating motif of CD2 abrogate antiviral activity. (A) Immunoblot analysis of encapsidation of APOBEC3G
mutants with individual amino acid residues in the conserved Zn2+ binding motif changed to Ala in CD1 (H65A, E67A, C97A and C100A) and CD2 (E259A).
Quantitative analysis, as performed in Fig. 1, is shown below. (B) Antiviral activity of the indicated mutated APOBEC3Gs was determined by single-cycle
luciferase reporter virus assay. Negative controls include infections using supernatant from 293T cells transfected with pcDNA alone or pcAPOBEC3G alone.
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cysteines in the active site of APOBEC3A are separated by
four amino acid residues and therefore is postulated not toFig. 5. APOBEC3G deaminase activity is mediated by the CD2 active site.
Virions containing wild-type or the indicated mutant APOBEC3G were
produced in 293T cells, pelleted and solubilized in detergent-containing
buffer to release the encapsidated enzyme. The lysates were incubated with
5V-(32P) labeled oligonucleotide and then cleaved at sites of CYU
deamination by treatment with UDG. As controls, virions were produced
in the absence of APOBEC3G (lane 1) or without viral plasmid (lane 2). An
oligonucleotide containing a dU in place of the target dC served as a marker
for the cleaved product (lane 8).coordinate zinc (Jarmuz et al., 2002). The proteins were
tested for binding to oligoribonucleotides that lacked C
and U (no C/U) that contained C (C-rich) or to
deoxyoligonucleotides lacking C (no C) or containing C
(C-rich) (Fig. 6). Wild-type APOBEC3G bound to
ribooligonucleotides regardless of its C-content and bound
to the deoxyoligonucleotides that contained C. Thus, the
enzyme bound nonspecifically to RNA but bound to DNA
that is targeted by for deamination. Control GST and GST-
APOBEC3A did not bind to nucleic acid. Alteration of the
Zn2+ coordination residues in CD1 dramatically reduced
the ability of the protein to bind RNA and DNA (Fig. 6).
Alteration of CD2 had no effect on binding of oligor-
ibonucleotides that contained C (C-rich) or deoxyoligonu-
cleotides that contained C. This mutant may have a
reduced ability to bind oligoribonucleotides that lacked C
and U although this difference could be within exper-
imental variability (no C/U) (Fig. 6). We concluded that
nucleic acid binding is primarily mediated by CD1.
CD1 Zn2+ coordination residues are required for
APOBEC3G dimerization
APOBEC1, APOBEC2, APOBEC3B and APOBEC3G
are homodimers (Jarmuz et al., 2002; Lau et al., 1994). To
determine which domains of APOBEC3G are required for
Fig. 6. RNA binding by APOBEC3G is primarily determined by CD1 Zn2+ coordination residues. APOBEC3A and APOBEC3G wild-type and the mutants
1CCAA and 2CCAA were produced in E. coli as GST fusion proteins and purified by affinity chromatography. 5V-end 33P labeled oligoribonucleotide was
incubated with the indicated APOBEC3G proteins. Two RNA oligonucleotides were used, one lacked C and U (no C/U) and one was enriched for C (C-rich)
and two DNA oligonucleotides were used, one lacking C (no C) and one enriched for C (C-rich). The complex was separated on native PAGE and exposed to
X-ray film. A low mobility nonspecific band is present for all proteins incubated with the no C/U oligoribonucleotide.
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with wild-type APOBEC3G was tested (Fig. 7). 293T cells
were cotransfected with equal amounts of mutated HA-
tagged APOBEC3G and wild-type myc-tagged APO-
BEC3G expression vector. Dimerization was assessed by
coimmunoprecipitation followed by immunoblot analysis.
Wild-type APOBEC3G-myc coimmunoprecipitated with
wild-type APOBEC3G-HA. In this analysis, the 2CCAA
protein dimerized but 1CCAA did not (Fig. 7). Thus, the
Zn2+ coordination residues in CD1 but not in CD2 are
required for dimerization of APOBEC3G.
CD1 mediates encapsidation of APOBEC3G into human T
cell leukemia virus type 1 (HTLV-I) and murine leukemia
virus (MuLV)
HTLV-I and HTLV-II do not encode Vif yet both
replicate in T cells. To determine whether HTLV-I encap-
sidated APOBEC3G and whether this affected its infectivity,
HTLV-I virions were produced in 293T using an HTLV-I
packaging construct and a luciferase encoding transfer
vector (Derse et al., 2001). The virions were produced inFig. 7. APOBEC3G dimerization requires CD1 Zn2+ coordination residues. 293T
vector. HA tagged APOBEC3G was wild-type, mutated in CD1 (1CCAA) or CD
fragment that includes aa 163 to 384 of APOBEC3G). Cell lysates were prepared
analyzed on immunoblots probed with anti-myc MAb. All of the proteins were ex
with empty vector (pcDNA) or APOBEC3G-myc alone (APO3G-myc).cells cotransfected with pc-APOBEC3G-HA and APO-
BEC3G content was determined by immunoblot analysis.
Encapsidated APOBEC3G was readily detected (Fig. 8A).
The analysis did not permit absolute quantitation, but the
intensity of the APOBEC3G and CA bands were similar to
those found for HIV-1 virions. Intracellular levels of
APOBEC3G were not affected by the presence of the
HTLV-I proteins in the transfected cells, suggesting that the
virus did not induce APOBEC3G degradation. The effect of
APOBEC3G on virion infectivity was determined by
titrating the amount of pcAPOBEC3G-HA plasmid and
including VSV-G vector to generate infectious pseudotypes.
The virus was then used to infect fresh 293T cells (Fig. 8B).
For comparison, Dvif HIV-1 virions were tested in parallel.
At the highest amount of pcAPOBEC3G (2 Ag), infectivity
was reduced about 2-fold. In contrast, the infectivity of Dvif
HIV-1 was reduced about 30-fold. With 1 Ag of pcAPO-
BEC3G HTLV-I infectivity was not significantly reduced
(Fig. 8B). Thus, HTLV-I, like MuLV (Mariani et al., 2003),
appeared to be relatively resistant to APOBEC3G.
To determine whether APOBEC3G was encapsidated
into divergent retroviruses by a mechanism similar to thatcells were cotransfected with HA or myc-tagged APOBEC3G expression
2 (2CCAA) Zn2+ coordination Cys residues or was deleted for CD1 (C-
and immunoprecipitated with anti-HA Mab. The immunoprecipitates were
pressed at similar levels (not shown). As controls, the cells were transfected
Fig. 8. HTLV-I is relatively resistant to encapsidated APOBEC3G. (A) HTLV-I virions were pelleted from the culture medium of 293T cells cotransfected with
the HTLV packaging plasmid pCMVHT-Denv, the transfer vector pHTC-luc (Derse et al., 2001) and pcAPOBEC3G-HA. APOBEC3G and HTLV-I CA p19
were visualized on immunoblots with anti-HA or anti-p19 MAb. (B). VSV-G pseudotyped HTLV-I luciferase reporter viruses were produced in 293T cells by
cotransfection with decreasing amounts of APOBEC3G expression vector (indicated below in Ag of transfected plasmid). Fresh 293T cells were infected with 2
ml of virus-containing supernatant. NL-Luc HIV-1 luciferase reporter viruses were prepared and analyzed in parallel. The results are representative of three
independent experiments.
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MuLV and HTLV-I was tested. As for HIV-1, the 1FYAA
mutant in which aromatic residues of CD1 were mutated
was not encapsidated into MuLVor HTLV-I. In contrast, the
2FFAA mutant was encapsidated in both viruses (Fig. 9).
The 2FFAA mutant was encapsidated at somewhat lower
efficiency into HTLV-I, which is consistent with the results
obtained for HIV-1 (compared to Fig. 3C). Overall,
APOBEC3G was encapsidated into MuLV and HTLV-I by
a mechanism that was similar to HIV-1.Discussion
The findings presented here suggest a model for
APOBEC3G function in which domain 1 directs encapsi-
dation and domain 2 serves as the catalytic site. The
antiviral activity of APOBEC3G requires the function of
both domains. In support of this model, domain 1 Zn2+
coordination amino acids were required for encapsidation,
while domain 2 Zn2+ coordination amino acids were
dispensable. A stable C-terminal fragment of APOBEC3Gwas not encapsidated. The active site of cytidine deaminase
domains contains an essential Glu residue. Domain 1 Glu67
was dispensable for antiviral activity while domain 2
Glu259 was required. It should be noted that E259A
retained weak antiviral activity, although no signal was
detected in the cytidine deaminase activity assay. The
residual antiviral activity could be taken to indicate an
antiviral activity separate from the deaminase activity
(Shindo et al., 2003; Turelli et al., 2004), but it is more
likely that the protein retains weak deaminase activity that is
beyond the limit of sensivity of the in vitro assay. Neither of
the catalytic Glu residues was required for encapsidation.
RNA binding by the APOBEC3G and homodimerization
were mediated by the domain 1 Zn2+ coordination residues.
It may be that a two-domain structure is needed for the
antiviral effect of APOBEC3 proteins in general, as the two
domain proteins APOBEC3B, APOBEC3F and APO-
BEC3G are active while APOBEC3A which consists of a
single domain is not (Bishop et al., 2004; Yu et al., 2004a).
The mechanism of APOBEC3G encapsidation has been
addressed in several recent reports. There is general agree-
ment that NC is an important determinant of APOBEC3G
Fig. 9. APOBEC3G encapsidation into MuLV and HTLV-I virions is dependent upon conserved aromatic residues in CD1. HTLV-I (right panel) and MuLV
(left panel) virions were generated by cotransfection of 293T cells with viral plasmid DNA and wild-type or mutant 1FYAA or 2FFAA APOBEC3G-HA
expression vector. Pelleted virions and cell lysates were analyzed on immunoblots probed with anti-HA or anti-p15 or anti-p19 MAbs as indicated at right. The
positions of APOBEC3G, MuLV CA p15 and HTLV CA p19 are shown on the left. Quantitative analysis, as performed in Fig. 1, is shown below.
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Douaisi et al., 2004; Luo et al., 2004; Schafer et al., 2004;
Zennou et al., 2004). However, because NC mediates viral
RNA packaging (Aldovini and Young, 1990; Gorelick et al.,
1990), it has been difficult to distinguish whether the
requirement stems from direct binding of APOBEC3G to
NC or to the viral RNA. Evidence that binding to NC was
sufficient was suggested by the finding that purified
recombinant APOBEC3G and NC directly interact (Alce
and Popik, 2004) and that RNase A treatment does not
interfere with the ability to coimmunoprecipitate Gag and
APOBEC3G from transfected cells (Cen et al., 2004;
Douaisi et al., 2004). However, others have found that the
interaction was sensitive to ribonucleases (Schafer et al.,
2004; Svarovskaia et al., 2004; Zennou et al., 2004). Viral
RNA packaging-deficient viruses incorporated normal
amounts of APOBEC3G, as shown here and by others
previously (Cen et al., 2004; Luo et al., 2004; Schafer et al.,
2004; Svarovskaia et al., 2004; Zennou et al., 2004).
However, such virions are likely to package cellular RNA
(Aronoff and Linial, 1991; Berkowitz et al., 1996) and these
could substitute for the viral RNA in facilitating APO-
BEC3G encapsidation. Although it is clear that viral RNA is
not required, our findings support a role for RNA in
APOBEC3G encapsidation. First, virions deleted for NC
consistently packaged about 10% the wild-type amount of
APOBEC3G, demonstrating that the virus has another
determinant for APOBEC3G encapsidation besides NC.
Second, mutations in APOBEC3G that affected RNA
binding blocked encapsidation. The Zn2+ coordination
residues of domain 1 which were required for RNA binding
were also required for APOBEC3G encapsidation. In
addition, the conserved aromatic residues F70 and Y91 of
CD1, which in APOBEC1 are required for RNA binding(Navaratnam et al., 1995) were also required for APO-
BEC3G encapsidation in HIV-1, MLV and HTLV-I.
Our findings differed somewhat from those of Cen et al.,
and Luo et al., who mapped an encapsidation determinant to
the N-terminal linker domain of APOBEC3G (Cen et al.,
2004; Luo et al., 2004). In those studies, the proteins were
encapsidated into Gag VLPs and not into native HIV-1
virions as in our study, although whether this could have
influenced the findings is not clear. Consistent with our
results, Li et al., found that a D1–67 APOBEC3G deletion
mutant, that lacks the conserved His of the first conserved
Zn2+ finger, was not encapsidated into DVif HIV-1 virions
(Li et al., 2004).
The ability of NC-deleted virions to encapsidate a small
but significant amount of APOBEC3G argues against a
simple protein–protein interaction between APOBEC3G
and NC. Moreover, the broad species-specificity of the
encapsidation also argues against this. APOBEC3G is
efficiently encapsidated by divergent retroviruses including
MuLV and HTLV-1 (Harris et al., 2003; Mangeat et al.,
2003; Mariani et al., 2003), the NC proteins of which are
highly divergent. Moreover, mouse APOBEC3, which has
only ~30% homology to the human protein is also
efficiently encapsidated in HIV-1 (Mariani et al., 2003). In
addition, it seems likely that if binding to NC was the sole
determinant of APOBEC3G encapsidation, the virus would
have escaped simply by altering the NC amino acid
sequence. A role for RNA in APOBEC3G encapsidation
would provide a mechanism from which the virus could not
easily escape. A role for RNA, however, presents the
paradox of how APOBEC3G is encapsidated into packaging
site mutant virions. Such virions are thought to package
cellular RNA yet it does not seem likely that APOBEC3G
molecules could coat much of the cellular mRNA. We
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mediated by a complex of NC with RNA in which
APOBEC3G binds to a composite site formed by the
complex of NC with RNA.
Lastly, we found that APOBEC3G could be encapsidated
in HTLV-I virions yet did not reduce its infectivity. HTLV-I
replicates in T cells yet does not encode a Vif-like protein
and did not appear to induce APOBEC3G degradation,
arguing that it does not encode a Vif analog. This finding
raises the question of how viruses such as HTLV-1 and
MuLV that lack Vif are able to replicate in the presence of
APOBEC3G. One possibility is that their reverse tran-
scription complex is not accessible to the encapsidated
deaminase. This further poses the question of why HIV-1
was not able to become resistant to deamination by a similar
mechanism but instead used the alternative strategy of
developing a novel gene as a means of escaping this cellular
antiviral activity.Materials and Methods
APOBEC3G expression vectors
HA and myc tagged human APOBEC3G expression
vectors pcAPOBEC3G-HA (Mariani et al., 2003) and
pcAPOBEC3G-myc were constructed by cloning a human
APOBEC3G cDNA into the EcoRI and XhoI sites of
pcDNA3.1(+) (Invitrogen) using primers that encoded the
corresponding C-terminal epitope tag. APOBEC3G mutants
were generated by overlapping PCR using pcAPOBEC3G-
HA as template. 5V and 3V fragments were amplified
separately with a primer specific for the overlap region
and a 5V external primer 5V-Apo3G.EcoRI (5V-TAG ATC
GAATTC ATG AAG CCT CAC TTC AGA AAC ACA G)
or a 3V primer 3V-Apo3G.HA.Xho (5V-ATT GAATCT CGA
GTC AAG CGT AAT CTG GAA CAT CGT ATG GAT
AGT TTT CCT GAT TCT GGA GAATGG CCC GCA G).
The 5V and 3V fragments were mixed and amplified with the
two external primers. The amplicon was cleaved with EcoRI
and XhoI and cloned into pcDNA3.1(+). All plasmids were
confirmed by sequencing. pcAPOBEC3G D128K has been
previously described (Schrofelbauer et al., 2004).
HIV-1 and HTLV-I proviral plasmids
Single cycle Dvif HIV-1 (pNL4-3 E R Dvif) provirus
and Dvif HIV-1 luciferase reporter virus (pNL-Luc-E R
Dvif) were previously described (Schrofelbauer et al., 2004).
Pr55 encodes a full-length HIV-1 genome with a point
mutation that inactivates protease (Accola et al., 2000). Zwt
mutant provirus does not contain p1, p6 and NC was
replaced with a yeast leucine zipper domain (Accola et al.,
2000). pMDLg/p is a CMV-driven expression plasmid that
contains only the gag and pol coding sequences from HIV-1
(Dull et al., 1998). HTLV-I virions were generated with theHTLV-I packaging plasmid, pCMVHT-Denv and transfer
vector pHTC-luc (Derse et al., 2001). MLV virions were
generated with Gag/Pol expression vector pHIT-60
(Soneoka et al., 1995).
Production of recombinant viruses and detection of
encapsidated APOBEC3G
APOBEC3G encapsidation into HIV-1, HTLV-I or MLV
virions was determined as previously described (Mariani et
al., 2003). 293T cells were maintained in Dulbecco’s
modified essential medium supplemented with 10% fetal
calf serum and antibiotics. Briefly, 293T cells were seeded
at 5  105 per well in 6 well plates. The following day, the
cells were cotransfected with 1 Ag each of pcAPOBEC3G-
HA and HIV-1, HTLV-I or MLV plasmid using Lipofect-
amine 2000 (Invitrogen). Two days later, virus containing
supernatants were collected and virions were ultracentri-
fuged through a 20% sucrose cushion at 150,000 g for
1.5 h. The pellets were solubilized in 100 Al of 1% Triton-
containing buffer and the proteins in 10 Al were separated
on 4–12% PAGE. The proteins were then transferred to
PDVF membranes and probed with anti-HA MAb 16B12
(Covance) followed by horseradish peroxidase-(HRP)
conjugated sheep anti-mouse Ig (Amersham). The mem-
branes were stripped and reprobed with anti-HIV-1 human
serum J810 (provided by Dr. Douglas Richman, UCSD),
anti-p24 MAb AG3.0, anti-HTLV-1 p19 MAb (Zymed) or
anti-MLV p15 goat serum followed by HRP conjugated
anti-human, anti-mouse or anti-goat IgG (Amersham) and
developed with ECL reagents (Amersham). Bands in
Western blots were quantitated by densitometry using
FluorChem 8000 (Alpha Innotech Corporation).
Dot blot analysis
Viral genomic RNA content of wild type and recombi-
nant HIV-1 virus was determined by dot blot analysis.
Briefly, virion supernatants from transfected 293T cells
were treated with 20 Ag/ml of DNaseI, RNase-free (Roche)
for 1 h at RT and then the virions were purified by
ultracentrifugation through 20% sucrose, resuspended in
PBS and normalized by p24. RNA was extracted from
equal amounts of p24 (200 ng) using Trizol Reagent
(Invitrogen) and then transferred to a nylon membrane
using a dot blot apparatus (Schleicher and Schuell). The
membrane was prehybridized 1 h at 68 8C in Express-Hyb
Hybridization solution (Clontech). Incubation with the
radiolabeled probe (106 cpm/ml) was for 2 h at 68 8C. As
probe we used an EcoRI/XhoI fragment of pNL4-3
(corresponding to nucleotides 5743 to 8887 of pNL4-3)
random labeled with a32P-dCTP (ICN) using High Prime
(Roche). The membrane was washed twice with 2 SSC–
0.05% SDS for 20 min at RT and once with 0.1 SSC–
0.1% SDS for 40 min at 50 8C and analyzed with a
PhosphorImager.
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239T cells were cotransfected in a six well dish with 1
Ag pcAPOBEC3G-HA or its mutated derivatives and 1 Ag
pcAPOBEC3G-myc. Two days posttransfection, the cells
were lysed in 1.0 ml CHAPS buffer (5 mM CHAPS, 50
mM Tris, pH 8.0, 50 mM NaCl) at 4 8C for 1 h. The lysates
were cleared by microcentrifugation for 20 min at 4 8C.
Lysates (250 Al) were precleared twice with 50 Al of a 1:1
slurry of protein-A sepharose for 30 min at 4 8C. Anti-HA
MAb (1 Ag) was added to 200 Al of precleared lysate and
incubated 2 h at 4 8C followed by addition of 30 Al of
protein-A sepharose beads. After 1 h, the beads were
collected and washed three times in 1 ml of CHAPS buffer
followed by two washes in 1 ml of 50 mM Tris, pH 8.0, 50
mM NaCl. The supernatant was removed and 15 Al of 2
reducing sample buffer (Invitrogen) was added. Samples
were heat to 958 for 5 min and then separated on 4–20%
SDS-PAGE. The proteins were transferred to PVDF
membranes and probed with anti-myc MAb 9E10 (Cova-
nce) followed by HRP-conjugated sheep anti-mouse Ig
(Amersham). The membranes were developed using ECL
Reagent (Amersham).
HIV-1 and HTLV-I luciferase reporter virus assay
VSV-G-pseudotpyed single-cycle HIV-1 and HTLV-I
luciferase reporter viruses were generated as previously
described (Connor et al., 1995; Derse et al., 2001). Briefly,
293T cells were cotransfected using Lipofectamine 2000
(Invitrogen) with 1 Ag of HIV-1 or HTLV-I luciferase
reporter virus, 1 Ag of wild type or mutant pcAPOBEC3G-
HA or pcDNA3.1(+) and 1 Ag of pcVSV-G. For
APOBEC3G titrations, the total amount of plasmid was
held constant by the addition of pcDNA3.1(+). Virus-
containing supernatant was harvested 2 days posttransfec-
tion filtered and the p24 concentration measured. 293T
cells (2  105) seeded the previous day in six-well plates
were infected with 300 Al of HIV-1 or 2 ml of HTLV-I
containing supernatant in the presence of 8 Ag/ml
polybrene (Sigma). After 6 h, medium was removed
and replaced with fresh medium. To assay for luciferase
activity, cells were harvested 72 h post infection, pelleted
and resuspended in 0.1 ml of lysis buffer (1% Triton X-
100, 50 mM NaCl, 10 mM Tris–HCl (pH 7.6), 5 mM
EDTA). Luciferase assays were performed with 20 Al of
cell extract in the Promega luciferase assay system
according to the manufacturer’s protocol. Data shown
are the mean cps +/ the standard error of the
triplicates.
APOBEC3G RNA binding assay
Vectors to produce recombinant APOBEC3 proteins
were constructed by transferring APOBEC cDNAs to
pGEX-6P-3 plasmid (Amersham) in-frame to the GSTcoding sequence at the EcoRI and XhoI sites. Recombinant
GST-APOBEC3G proteins (wild-type, CD1 1CCAA and
CD2 2CCAA mutants) and GST-APOBEC3A were pro-
duced in E. coli BL21-DE3 induced with 0.5 mM IPTG.
Bacteria were pelleted and lysed in PBS containing 10 mM
EDTA/5 mM dithiothreitol/1% triton-X100. The proteins
were purified by affinity chromatography on glutathione
sepharose beads. DNA and RNA oligonucleotides
described by Yu et al. (2004b) were 5V-end labeled with
33P-gATP using T4 polynucleotide kinase and unincorpo-
rated nucleotide was removed on G25 spin column. Each
protein (2 Ag) was incubated with oligonucleotide (1  105
cpm) in binding buffer (10 mM HEPES, 10% glycerol, 100
mM KCl, 10 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT) at
378 for 40 min and then separated by native PAGE on a 4–
20% gradient gel. The gel was dried and exposed to
Biomax MR (Kodak) film overnight.
Cytidine deaminase assay
Virions were generated by cotransfection of 293T cells
with 1:1 ratio of Dvif pNL4-3 and pcAPOBEC3G-HA.
Supernatant was harvested 3 days posttransfection, filtered
and pelleted through 2 ml of 20% (w/v) sucrose/PBS by
ultracentrifugation for 1h at 35,000 RPM in an SW41 rotor.
Pelleted virions were lysed in 100 Al buffer containing 50
mM Tris (pH 8.0), 40 mM KCl, 50 mM NaCl, 5 mM
EDTA, 10 mM DTT and 0.1% (v/v) triton-X100. Lysates
were normalized for p24 concentration. The virus lysate
(100 ng p24) was mixed with 1  105 cpm of 5V-end
labeled oligonucleotide with the sequence 5V-TTT TTT
TTT TTT TTT CCC GTT TTT TTT TTT TTT TTT TTT
TT T in deaminase buffer (40 mM Tris, pH 8.0, 40 mM
KCl, 50 mM NaCl, 5M EDTA, 10% (v/v) glycerol, 1 mM
DTT). After 5 h at 37 8C, the reactions were terminated by
heating to 90 8C for 5 min. The oligonucleotide was then
treated with uracil DNA glycosylase (UDG) for 30 min at
37 8C in UDG buffer (20 mM Tris, pH 8.0, 1 mM DTT)
and cleaved by treatment with 0.15 M NaOH at 37 8C for
30 min. The products were separated on 15% TBE-urea
PAGE and detected by autoradiography. A labeled marker
oligonucleotide in which the target C was replaced with U
was processed in parallel to indicate the position of the
cleaved product.Acknowledgments
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